Dr. Shirley Catherine Paski, MD

Dr. Paski practices at Cleveland Clinic Main Campus in Cleveland, Ohio, part of The Cleveland Clinic Foundation.

Dr. Paski's NPI, 1518264746, was assigned on February 24, 2011. Dr. Paski holds Ohio license 35.145922.

Dr. Paski's primary practice is Cleveland Clinic Main Campus, at 9500 Euclid Avenue, Cleveland, OH 44195 in Cuyahoga County. The practice phone is (216) 952-9829.

Dr. Paski's primary practice is Cleveland Clinic Main Campus in Cleveland, Ohio, part of The Cleveland Clinic Foundation. Dr. Paski is also affiliated with Fairview Hospital. The medical group on file is Cleveland Clinic. Dmand AI also links Dr. Paski to 3 more hospitals, 2 clinical labs, 1 group practice or clinic and 1 medical group, each named with a free account. Dr. Paski's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Paski practices, 8 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Paski's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dmand AI has Dr. Paski's licenses on file in 4 states: Ohio, California, Illinois and Washington.

CMS data shows 483 Medicare services from Dr. Paski across 9 procedure codes in 2024, for 255 Medicare patients. Medicare paid $41,093 for them.

CMS counts 255 Medicare patients who saw Dr. Paski in 2024. The largest group is 65 to 74, with 102 patients. 75% of them have high blood pressure, and 67% have high cholesterol. 20% are also on Medicaid. Their average risk score is 2.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Paski's median patient age at 58, with 64% women.

In 2024, Dr. Paski wrote 1,991 Medicare Part D claims for 166 patients. 52% of them were for generic drugs. CMS names the drug for 1,834 of them, across 30 drugs with 11 or more claims each, at $3,912,486 in total drug cost. In 2023, CMS named 1,198 claims across 21 drugs.

Dr. Paski accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Paski as offering telehealth. CMS counts 35 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Paski, more than 58% of the clinicians it reports for that procedure.

Dmand AI links 15 papers to Dr. Paski, published from 2012 to 2024. 2021 was the busiest year, with 2. The most frequent topics are Celiac Disease, Diet and Inflammatory Bowel Diseases. Dr. Paski has published most often in Gastroenterology. Dr. Paski's most frequent co-authors are Andrew Eugene Hendifar, MD, MPH, Jessica Crystal, MD and Alexandra Gangi, MD.

Dmand AI links Dr. Paski to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Short Bowel Syndrome and Malabsorption Syndromes.

CMS Open Payments shows 16 general payments to Dr. Paski from 10 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 77% of the total. Takeda Pharmaceuticals U.S.A., Inc. paid the most, $3,620.